Focus: MyOme is a genomic analysis biotechnology company focused on precision medicine diagnostics across neurology, cardiovascular, and rare diseases. Based in Palo Alto, the company operates at an early stage with a lean footprint and research-driven business model.
Profile data last refreshed 11h ago · AI intelligence enriched 3w ago
Stable — net +2 jobs in 30d
8 added, 6 removed. Backfill posture.
MyOme is a high-risk, high-learning opportunity for scientists and R&D professionals seeking early-stage genomics exposure; unsuitable for those prioritizing salary stability or near-term commercial milestones.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MyOme
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MyOme's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
MyOme Strengthens Board with Appointment of Two Healthcare Leaders - PR Newswire
MyOme Strengthens Board with Appointment of Two Healthcare Leaders PR Newswire
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis - BioSpace
Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis BioSpace
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 9 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo